Abstract:Abstract Background The discovery of the importance of angiogenesis in tumor growth has emphasized the need to find specific vascular targets for tumor-targeted therapies. Previously, using phage display technology, we identified the peptide GX1 as having the ability to target the gastric cancer vasculature. The present study investigated the bioactivities of GX1, as well as its potential ability to cooperate with recombinant mutant human tumor necrosis factor alpha (rmhTNFα), in gastric cancer therapy. Results Tetrazolium salt (MTT) assay showed that GX1 could inhibit cell proliferation of both human umbilical vein endothelial cells (HUVEC) (44%) and HUVEC with tumor endothelium characteristics, generated by culturing in tumor-conditioned medium (co-HUVEC) (62%). Flow-cytometry (FCM) and western blot assays showed that GX1 increased the rate of apoptosis from 11% to 31% (p < 0.01) by up-regulating caspase 3 expression level. A chorioallantoic membrane assay indicated that GX1 could suppress neovascularization in vivo, with the microvessel count decreasing from 21 to 11 (p < 0.05). When GX1 was fused to rmhTNFα, GX1-rmhTNFα selectively concentrated in the gastric cancer vasculature, as shown by enzyme-linked immunosorbent assay, immunofluorescence and emission-computed tomography. In vitro MTT and FCM assays showed that, compared to rmhTNFα alone, GX1-rmhTNFα was more effective at suppressing co-HUVEC proliferation (45% vs. 61%, p < 0.05) and inducing apoptosis (11% vs. 23%, p < 0.05). In a tumor formation test, GX1-rmhTNFα more effectively inhibited tumor growth than rmhTNFα (tumor volume: 271 mm3 vs. 134 mm3, p < 0.05), with less systemic toxicity as measured by body weight (20.57 g vs. 19.30 g, p < 0.05). These therapeutic effects may be mediated by selectively enhanced tumor vascular permeability, as indicated by Evan's blue assay. Conclusion GX1 had both homing activity and the ability to inhibit vascular endothelial cell proliferation in vitro and neovascularization in vivo. Furthermore, when GX1 was conjugated to rmhTNFα, the fusion protein was selectively delivered to targeted tumor sites, significantly improving the anti-tumor activity of rmhTNFα and decreasing systemic toxicity. These results demonstrate the potential of GX1 as a homing peptide in vascular targeted therapy for gastric cancer.

Therapeutic Potential of Capillary Morphogenesis Gene 2 Extracellular Vwa Domain in Tumour-Related Angiogenesis

Capillary Morphogenesis Gene 2 Regulates Adhesion and Invasiveness of Prostate Cancer Cells.

Capillary Morphogenesis Gene 2 Inhibits Growth of Breast Cancer Cells and is Inversely Correlated with the Disease Progression and Prognosis

Anti-metastatic effects of DNA vaccine encoding single-chain trimer composed of MHC I and vascular endothelial growth factor receptor 2 peptide.

Vascular Basement Membrane-Derived Multifunctional Peptide, A Novel Inhibitor of Angiogenesis and Tumor Growth

O1 Elevated Expression Level of Capillary Morphogenesis Gene 2 in Pancreatic Ductal Adenocarcinoma Cell is Associated with Distant Metastasis and Poor Prognosis

Inhibition of Tumor Angiogenesis in Lung Cancer by T4 Phage Surface Displaying Mvegfr2 Vaccine

Eukaryotic Expression of Extracellular Ligand Binding Domains of Murine Tie‐2 and Its Anti‐angiogenesis Effect in SGC‐7901 Cell Lines

Promotive effects of capillary morphogenetic protein 2 on glioma cell invasion and the molecular mechanism.

Efficacy of Dendrimer-Mediated Angiostatin and Timp-2 Gene Delivery on Inhibition of Tumor Growth and Angiogenesis: in Vitro and in Vivo Studies

Implication of Capillary Morphogenesis Gene 2 (CMG2) in the Disease Progression and Peritoneal Metastasis of Pancreatic Cancer

Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor

A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor Activities

A Gene Therapy for Cancer Based on the Angiogenesis Inhibitor, Vasostatin.

Vegf Kinoid Vaccine, A Therapeutic Approach Against Tumor Angiogenesis And Metastases

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Antitumour Immunity Mediated by Mannan-Modified Adenovirus Vectors Expressing VE-cadherin

Regulation of angiogenesis by signal sequence-derived peptides

Molecular Mechanisms of Thrombospondin-2 Modulates Tumor Vasculogenic Mimicry by PI3K/AKT/mTOR Signaling Pathway

A Novel Peptide (GX1) Homing to Gastric Cancer Vasculature Inhibits Angiogenesis and Cooperates with TNF Alpha in Anti-Tumor Therapy

Inhibition of Endothelial SCUBE2 (Signal Peptide-CUB-EGF Domain-Containing Protein 2), a Novel VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) Coreceptor, Suppresses Tumor Angiogenesis.